Mechanism of Action
TGF-beta Receptor Signaling
GDF-11 signals through ALK4/5/7 receptor complexes and co-receptors ActRIIA/B (activin receptors), activating SMAD2/3 phosphorylation and downstream transcriptional programs. These pathways regulate cell cycle, differentiation, and senescence across multiple tissue types. GDF-11 shares ~90% sequence homology with GDF-8 (myostatin) in the mature domain, this similarity complicates measurement studies and suggests overlapping receptor pharmacology. Unlike myostatin, GDF-11 appears to have context-dependent tissue effects: inhibitory in some cell populations and trophic in others.
Neurogenesis and Brain Effects
Katsimpardi et al (Science, 2014) showed systemic GDF-11 administration in aged mice increased cerebrovascular density and olfactory neurogenesis to levels comparable to young mice, alongside improved olfactory discrimination. These effects were attributed to GDF-11's ability to stimulate adult neural stem/progenitor cell proliferation. SMAD2/3 signaling in neurogenic niches (hippocampal dentate gyrus, olfactory subventricular zone) appears to mediate the neurogenic response. This work, if confirmed, has profound implications for age-related cognitive decline.
Cardiac and Skeletal Muscle Effects (Controversy)
Loffredo et al (Cell, 2013) reported that GDF-11 reversed age-related cardiac hypertrophy in mice, as measured by heart weight and cardiomyocyte cross-section. Glass et al's 2015 rebuttal argued that circulating GDF-11 does not decline with age when properly measured, and that it does not reverse cardiac hypertrophy. Subsequent independent studies have found inconsistent results. More recent proteomic aging clocks do include GDF-11-related proteins among aging biomarkers, suggesting a real signal exists, the controversy may partially reflect measurement artifacts with anti-GDF-11 antibodies that cross-react with myostatin.
Research Summary
Parabiosis and Young Blood Studies
EmergingThe landmark 2013-2014 parabiosis papers showed that connecting the circulation of young and old mice (via shared vasculature) reversed multiple age-related phenotypes. GDF-11 was proposed as a key circulating factor. The scientific debate that followed was unusual in its intensity and public profile. Current consensus acknowledges that young blood contains multiple beneficial factors and that GDF-11 is one of several candidates, but that its specific contribution and dose-response in humans is not established.
Skeletal Muscle Regeneration
Moderate EvidenceA 2014 Science paper by Sinha et al showed GDF-11 treatment restored satellite cell function in aged mice (measured by regeneration after cardiotoxin injury), independent of the cardiac controversy. Satellite cell numbers and regenerative capacity increased significantly. This specific finding has been less contested than the cardiac data.
Calculate your GDF-11 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-aging / longevity | 100-150 mcg | 1-2x/week for 4-8 weeks | Subcutaneous |
| Muscle repair | 50-100 mcg | 2x/week for 3-4 weeks | Subcutaneous |
| Neurological support | 100 mcg | Weekly for 4-8 weeks | Subcutaneous |
GDF-11 research is genuinely in flux, interpretations of efficacy vary across labs. Users should be aware that the evidence base is primarily rodent, and the controversy about its actual aging-related changes in humans is unresolved. Conservative cycling and monitoring is advised.
Interactions
Safety Profile
GDF-11's close homology to myostatin raises theoretical concerns about muscle mass at supraphysiologic doses, myostatin is a potent negative regulator of muscle growth and GDF-11 may share this property. In mouse studies, excess GDF-11 caused wasting, while age-appropriate levels appeared beneficial. The dose-response curve may be narrow. No human clinical data exists for injectable GDF-11. The primary safety unknown is oncological: TGF-beta superfamily members have complex roles in cancer biology, acting as tumor suppressors in early disease but potentially tumor-promoting in established cancers via immunosuppressive SMAD signaling. Not WADA prohibited. Not FDA approved.
References
- [1]Loffredo FS et al. "Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy." Cell. 2013;153(4):828-839.
- [2]Katsimpardi L et al. "Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors." Science. 2014;344(6184):630-634.
- [3]Sinha M et al. "Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle." Science. 2014;344(6184):649-652.
- [4]Egerman MA et al. "GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration." Cell Metab. 2015;22(1):164-174.